Bone marrow microenvironment in an in vitro model of gaucher disease: Consequences of glucocerebrosidase deficiency

Stem Cells and Development

Volumn 21, Issue 2, 2012, Pages 239-248

  Lecourt, Séverine ^a,b,c   Vanneaux, Valérie ^a,b,c   Cras, Audrey ^a,b,c   Freida, Delphine ^a,b   Heraoui, Djazia ^d   Herbi, Linda ^a,b,c   Caillaud, Catherine ^e   Chomienne, Christine ^c   Marolleau, Jean Pierre ^f   Belmatoug, Nadia ^d   Larghero, Jérôme ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d BEAUJON HOSPITAL   (France)

^e Hôpital Cochin ^*  (France)

^f AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CONDURITOL BETA EPOXIDE; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW; BONE METABOLISM; CELL DIFFERENTIATION; CELL ISOLATION; CELL STRUCTURE; CHEMICAL MODEL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GAUCHER DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MICROENVIRONMENT; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL EXPANSION; WESTERN BLOTTING;

BONE MARROW; BONE RESORPTION; CELL CYCLE; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; CULTURE MEDIA, CONDITIONED; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INOSITOL; MESENCHYMAL STEM CELLS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOCLASTS;

EID: 84855857674     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0365     Document Type: Article

References (54)

1. Grabowski GA. (2008). Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 372:1263-1271.
2. Beutler E and GA Grabowski. (2001). Glucosylceramide Lipi-dosis-Gaucher Disease. McGraw-Hill, New York.
3. Charrow J, HC Andersson, P Kaplan, EH Kolodny, P Mistry, G Pastores, BE Rosenbloom, CR Scott, RS Wappner, NJ Weinreb and A Zimran. (2000). The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160:2835-2843.
4. Allen MJ, BJ Myer, AM Khokher, N Rushton and TM Cox. (1997). Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 90:19-25. (Pubitemid 27075848)
5. Barak V, M Acker, B Nisman, I Kalickman, A Abrahamov, A Zimran and S Yatziv. (1999). Cytokines in Gaucher's disease. Eur Cytokine Netw 10:205-210. (Pubitemid 29332776)
6. Ciana G, C Martini, A Leopaldi, G Tamaro, F Katouzian, L Ronfani and B Bembi. (2003). Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72:185-189. (Pubitemid 36919522)
7. de Fost M, TA Out, FA de Wilde, EP Tjin, ST Pals, MH van Oers, RG Boot, JF Aerts, M Maas, S Vom Dahl and CE Hollak. (2008). Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87:439-449.
8. Hollak CE, M Levi, F Berends, JM Aerts and MH van Oers. (1997). Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96:470-476. (Pubitemid 27087229)
9. van Breemen MJ, M de Fost, JS Voerman, JD Laman, RG Boot, M Maas, CE Hollak, JM Aerts and F Rezaee. (2007). Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772:788-796. (Pubitemid 46891215)
10. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147. (Pubitemid 29282067)
11. Berger J, S Lecourt, V Vanneaux, C Rapatel, S Boisgard, C Caillaud, N Boiret-Dupre, C Chomienne, JP Marolleau, J Larghero and MG Berger. (2010). Glucocerebrosidase deficiency dramatically impairs human bone marrow haemato-poiesis in an in vitro model of Gaucher disease. Br J Haematol 150:93-101.
12. Campeau PM, M Rafei, MN Boivin, Y Sun, GA Grabowski and J Galipeau. (2009). Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 114:3181-3190.
13. Mistry PK, J Liu, M Yang, T Nottoli, J McGrath, D Jain, K Zhang, J Keutzer, WL Chuang, et al. (2010). Glucocer-ebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 107:19473-19478.
14. Peters SP, P Coyle and RH Glew. (1976). Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys 175:569-582.
15. Arnulf B, S Lecourt, J Soulier, B Ternaux, MN Lacassagne, A Crinquette, J Dessoly, AK Sciaini, et al. (2007). Phenotypic and functional characterization of bone marrow mesenchy-mal stem cells derived from patients with multiple myeloma. Leukemia 21:158-163. (Pubitemid 44921847)
16. Lorincz M, LA Herzenberg, Z Diwu, JA Barranger and WG Kerr. (1997). Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood 89:3412-3420. (Pubitemid 27229829)
17. Rudensky B, E Paz, G Altarescu, D Raveh, D Elstein and A Zimran. (2003). Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells Mol Dis 30:97-99. (Pubitemid 36378870)
18. Yatziv S, DS Newburg, N Livni, G Barfi and EH Kolodny. (1988). Gaucher-like changes in human blood-derived macrophages induced by beta-glucocerebrosidase inhibition. J Lab Clin Med 111:416-420.
19. Das PK, GJ Murray, AE Gal and JA Barranger. (1987). Glu-cocerebrosidase deficiency and lysosomal storage of gluco-cerebroside induced in cultured macrophages. Exp Cell Res 168:463-474.
20. Schwarz A and AH Futerman. (1998). Inhibition of sphin-golipid synthesis, but not degradation, alters the rate of dendrite growth in cultured hippocampal neurons. Brain Res Dev Brain Res 108:125-130. (Pubitemid 28332825)
21. Korkotian E, A Schwarz, D Pelled, G Schwarzmann, M Segal and AH Futerman. (1999). Elevation of intracellular gluco-sylceramide levels results in an increase in endoplasmic re-ticulum density and in functional calcium stores in cultured neurons. J Biol Chem 274:21673-21678.
22. Schueler UH, T Kolter, CR Kaneski, GC Zirzow, K Sandhoff and RO Brady. (2004). Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27:649-658. (Pubitemid 39295107)
23. Lamghari M, CC Barrias, C Sa Miranda and MA Barbosa. (2005). Recombinant glucocerebrosidase uptake by Gaucher disease human osteoblast culture model. Blood Cells Mol Dis 35:348-354. (Pubitemid 41630720)
24. Hein LK, PJ Meikle, JJ Hopwood and M Fuller. (2007). Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab 92:336-345. (Pubitemid 350117716)
25. Legler G. (1973). Active site directed inhibitors and mechanism of action of glycosidases. Mol Cell Biochem 2: 31-38.
26. Mayack SR and AJ Wagers. (2008). Osteolineage niche cells initiate hematopoietic stem cell mobilization. Blood 112: 519-531.
27. Boyle WJ, WS Simonet and DL Lacey. (2003). Osteoclast differentiation and activation. Nature 423:337-342. (Pubitemid 40852708)
28. Majumdar MK, MA Thiede, SE Haynesworth, SP Bruder and SL Gerson. (2000). Human marrow-derived mesenchy-mal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 9:841-848. (Pubitemid 32110282)
29. Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74. (Pubitemid 27161245)
30. Beutler E and W Kuhl. (1970). The diagnosis of the adult type of Gaucher's disease and its carrier state by demonstration of deficiency of beta-glucosidase activity in peripheral blood leukocytes. J Lab Clin Med 76:747-755.
31. Fuller M, T Rozaklis, M Lovejoy, K Zarrinkalam, JJ Hopwood and PJ Meikle. (2008). Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease. Mol Genet Metab 93:437-443.
32. Kozutsumi Y, T Kanazawa, Y Sun, T Yamaji, H Yamamoto and H Takematsu. (2002). Sphingolipids involved in the induction of multinuclear cell formation. Biochim Biophys Acta 1582:138-143. (Pubitemid 34634122)
33. Webster M, KL Witkin and O Cohen-Fix. (2009). Sizing up the nucleus: nuclear shape, size and nuclear-envelope assembly. J Cell Sci 122:1477-1486.
34. Hein LK, S Duplock, JJ Hopwood and M Fuller. (2008). Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 49:1725-1734.
35. Dalle Carbonare L, MT Valenti, M Zanatta, L Donatelli and V Lo Cascio. (2009). Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum 60:3356-3365.
36. Giuliani N, S Colla, F Morandi, M Lazzaretti, R Sala, S Bo-nomini, M Grano, S Colucci, M Svaldi and V Rizzoli. (2005). Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472-2483. (Pubitemid 41510822)
37. Vejlgaard T, N Abildgaard, H Jans, JL Nielsen and L Heickendorff. (1997). Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol 58:104-108. (Pubitemid 27140395)
38. Yoshino M, Y Watanabe, Y Tokunaga, E Harada, C Fujii, S Numata, M Harada, A Tajima and H Ida. (2007). Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int 49:959-965. (Pubitemid 350197159)
39. Hollak CE, L Evers, JM Aerts and MH van Oers. (1997). Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201-212. (Pubitemid 27469455)
40. Michelakakis H, C Spanou, A Kondyli, E Dimitriou, S Van Weely, CE Hollak, MH Van Oers and JM Aerts. (1996). Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317:219-222. (Pubitemid 26426550)
41. Tuchman LR, G Goldstein and M Clyman. (1959). Studies on the nature of the increased serum acid phosphatase in Gaucher's disease. Am J Med 27:959-962.
42. Lacerda L, FA Arosa, R Lacerda, J Cabeda, G Porto, O Amaral, A Fortuna, R Pinto, P Oliveira, et al. (1999). T cell numbers relate to bone involvement in Gaucher disease. Blood Cells Mol Dis 25:130-138. (Pubitemid 29298192)
43. Drugan C, G Jebeleanu, P Grigorescu-Sido, C Caillaud and AM Craciun. (2002). Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. Blood Cells Mol Dis 28:13-20. (Pubitemid 34408983)
44. Stowens DW, SL Teitelbaum, AJ Kahn and JA Barranger. (1985). Skeletal complications of Gaucher disease. Medicine (Baltimore) 64:310-322. (Pubitemid 16224046)
45. Moran MT, JP Schofield, AR Hayman, GP Shi, E Young and TM Cox. (2000). Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including os-teoclastic cathepsin K. Blood 96:1969-1978. (Pubitemid 30662113)
46. Boven LA, M van Meurs, RG Boot, A Mehta, L Boon, JM Aerts and JD Laman. (2004). Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359-369. (Pubitemid 39145540)
47. Kim MS, CJ Day, CI Selinger, CL Magno, SR Stephens and NA Morrison. (2006). MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem 281:1274-1285.
48. Bendre MS, DC Montague, T Peery, NS Akel, D Gaddy and LJ Suva. (2003). Interleukin-8 stimulation of osteoclastogen-esis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone 33:28-37. (Pubitemid 36952685)
49. Solary E, M Guiguet, V Zeller, RO Casasnovas, D Caillot, P Chavanet, H Guy and G Mack. (1992). Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma. Am J Hematol 39:163-171.
50. Roodman GD, N Kurihara, Y Ohsaki, A Kukita, D Hosking, A Demulder, JF Smith and FR Singer. (1992). Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 89:46-52.
51. Tian E, F Zhan, R Walker, E Rasmussen, Y Ma, B Barlogie and JD Shaughnessy, Jr. (2003). The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494. (Pubitemid 38010074)
52. Grassi F, S Cristino, S Toneguzzi, A Piacentini, A Facchini and G Lisignoli. (2004). CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 199:244-251. (Pubitemid 38436751)
53. Zannettino AC, AN Farrugia, A Kortesidis, J Manavis, LB To, SK Martin, P Diamond, H Tamamura, T Lapidot, N Fujii and S Gronthos. (2005). Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:1700-1709. (Pubitemid 40478595)
54. Enquist IB, E Nilsson, A Ooka, JE Mansson, K Olsson, M Ehinger, RO Brady, J Richter and S Karlsson. (2006). Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 103:13819-13824. (Pubitemid 44413991)